HRP20171477T1 - Kristalični oblici od 5-kloro-n2-(2-izopropoksi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina - Google Patents

Kristalični oblici od 5-kloro-n2-(2-izopropoksi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina Download PDF

Info

Publication number
HRP20171477T1
HRP20171477T1 HRP20171477TT HRP20171477T HRP20171477T1 HR P20171477 T1 HRP20171477 T1 HR P20171477T1 HR P20171477T T HRP20171477T T HR P20171477TT HR P20171477 T HRP20171477 T HR P20171477T HR P20171477 T1 HRP20171477 T1 HR P20171477T1
Authority
HR
Croatia
Prior art keywords
cancer
phenyl
piperidin
crystalline form
isopropoxy
Prior art date
Application number
HRP20171477TT
Other languages
English (en)
Croatian (hr)
Inventor
Lili Feng
Baoqing Gong
Piotr H. Karpinski
Liladhar Murlidhar Waykole
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45464892&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20171477(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20171477T1 publication Critical patent/HRP20171477T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Hydrogenated Pyridines (AREA)
HRP20171477TT 2010-12-17 2011-12-15 Kristalični oblici od 5-kloro-n2-(2-izopropoksi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina HRP20171477T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061424194P 2010-12-17 2010-12-17
PCT/US2011/065030 WO2012082972A1 (en) 2010-12-17 2011-12-15 Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine
EP11806079.7A EP2651918B1 (en) 2010-12-17 2011-12-15 Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine

Publications (1)

Publication Number Publication Date
HRP20171477T1 true HRP20171477T1 (hr) 2017-11-17

Family

ID=45464892

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20171477TT HRP20171477T1 (hr) 2010-12-17 2011-12-15 Kristalični oblici od 5-kloro-n2-(2-izopropoksi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina
HRP20181737TT HRP20181737T1 (hr) 2010-12-17 2018-10-22 Kristalni oblici od 5-kloro-n2-(2-izopropoksi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20181737TT HRP20181737T1 (hr) 2010-12-17 2018-10-22 Kristalni oblici od 5-kloro-n2-(2-izopropoksi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina

Country Status (36)

Country Link
US (2) US9309229B2 (OSRAM)
EP (3) EP3453708B8 (OSRAM)
JP (1) JP5916752B2 (OSRAM)
KR (4) KR20190022903A (OSRAM)
CN (7) CN112125884A (OSRAM)
AR (2) AR084309A1 (OSRAM)
AU (1) AU2011343775B2 (OSRAM)
BR (1) BR112013015000A2 (OSRAM)
CA (1) CA2821102C (OSRAM)
CL (1) CL2013001723A1 (OSRAM)
CO (1) CO6801792A2 (OSRAM)
CY (2) CY1119474T1 (OSRAM)
DK (2) DK3121171T3 (OSRAM)
EC (1) ECSP13012770A (OSRAM)
ES (3) ES2696526T3 (OSRAM)
GT (1) GT201300153A (OSRAM)
HR (2) HRP20171477T1 (OSRAM)
HU (1) HUE041845T2 (OSRAM)
IL (1) IL226474A (OSRAM)
LT (2) LT3121171T (OSRAM)
MA (1) MA34771B1 (OSRAM)
MX (1) MX338210B (OSRAM)
MY (2) MY177742A (OSRAM)
NZ (1) NZ610713A (OSRAM)
PE (1) PE20140698A1 (OSRAM)
PH (1) PH12013501254A1 (OSRAM)
PL (2) PL2651918T3 (OSRAM)
PT (2) PT3121171T (OSRAM)
RS (1) RS57771B1 (OSRAM)
RU (2) RU2746159C2 (OSRAM)
SG (2) SG10201510082XA (OSRAM)
SI (2) SI3121171T1 (OSRAM)
TN (1) TN2013000216A1 (OSRAM)
TW (2) TWI576343B (OSRAM)
WO (1) WO2012082972A1 (OSRAM)
ZA (1) ZA201303599B (OSRAM)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS57771B1 (sr) * 2010-12-17 2018-12-31 Novartis Ag Kristalni oblici 5-hloro-n2-(2-izopropoksi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina
BR112015010221B1 (pt) 2012-11-06 2022-09-13 Shanghai Fochon Pharmaceutical Co., Ltd. Inibidores de quinase alk, seus usos, composição farmacêutica, e método para fabricação de medicamento
KR101656382B1 (ko) * 2014-02-28 2016-09-09 한국화학연구원 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물
CN105272921A (zh) * 2014-06-09 2016-01-27 江苏奥赛康药业股份有限公司 一种制备Ceritinib的方法及其中间体化合物
CN105294649B (zh) * 2014-07-30 2019-05-14 江苏奥赛康药业股份有限公司 一种Ceritinib化合物及其药物组合物
CN105294650A (zh) * 2014-08-01 2016-02-03 江苏奥赛康药业股份有限公司 一种Ceritinib化合物及其药物组合物
EP3760618A1 (en) 2014-10-21 2021-01-06 ARIAD Pharmaceuticals, Inc. Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl]pyrimidine-2,4-diamine
WO2016081538A1 (en) 2014-11-18 2016-05-26 Teva Pharmaceuticals International Gmbh Solid state forms of ceritinib and salts thereof
CN105601614A (zh) * 2014-11-21 2016-05-25 奥浦顿（上海）医药科技有限公司 一种色瑞替尼晶型及其制备方法
WO2016082795A1 (zh) * 2014-11-28 2016-06-02 苏州晶云药物科技有限公司 色瑞替尼的晶型i及其制备方法
CN105622577A (zh) * 2014-11-29 2016-06-01 江苏先声药业有限公司 一种色瑞替尼的新晶型及其制备方法
WO2016108123A2 (en) * 2014-12-17 2016-07-07 Dr. Reddy’S Laboratories Limited Pure amorphous and amorphous solid dispersion of ceritinib
WO2016098042A1 (en) * 2014-12-19 2016-06-23 Novartis Ag Use of ceritinib (ldk-378) in the treatment of fes or fer mediated disorders, in particular proliferative disorders
WO2016098070A1 (en) 2014-12-19 2016-06-23 Novartis Ag Crystalline form of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine
EP3328848A1 (en) 2015-07-28 2018-06-06 Zentiva, K.S. Solid forms of ceritinib free base
CN105061397B (zh) * 2015-08-07 2018-01-02 武汉英普瑞医药科技有限公司 一种色瑞替尼的c型晶型及其制备方法与应用
CN106699743B (zh) 2015-11-05 2020-06-12 湖北生物医药产业技术研究院有限公司 嘧啶类衍生物及其用途
WO2017152858A1 (zh) * 2016-03-11 2017-09-14 苏州晶云药物科技有限公司 色瑞替尼的晶型及其制备方法
US10604505B2 (en) 2016-03-15 2020-03-31 Natco Pharma Limited Modified process for the preparation of Ceritinib and amorphous form of Ceritinib
JP2019196359A (ja) * 2019-06-17 2019-11-14 ノバルティス アーゲー ピリミジン誘導体およびそれらの中間体を調製する化学的方法
GB201915618D0 (en) 2019-10-28 2019-12-11 Univ Oslo ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseases
EP4092021B1 (en) * 2020-01-17 2025-11-12 Xuanzhu Biopharmaceutical Co., Ltd. Crystal form of polycyclic anaplastic lymphoma kinase inhibitor
MX2022011768A (es) * 2020-03-30 2022-10-18 Jiangsu Yahong Meditech Co Ltd Forma cristalina del profarmaco de nitroxolina, la composicion farmaceutica que la contiene, y el metodo de preparacion y aplicacion de la misma.
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
PL2287156T3 (pl) * 2003-08-15 2013-11-29 Novartis Ag 2,4-Di(fenyloamino)-pirymidyny stosowane w leczeniu chorób nowotworowych, chorób zapalnych i zaburzeń układu immunologicznego
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
CN101616895A (zh) 2006-12-08 2009-12-30 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
PL2091918T3 (pl) * 2006-12-08 2015-02-27 Novartis Ag Związki i kompozycje jako inhibitory kinazy białkowej
MX2010002336A (es) * 2007-08-28 2010-03-25 Irm Llc Derivados de 2-bifenil-amino-4-amino-pirimidina como inhibidores de cinasa.
WO2009032703A1 (en) * 2007-08-28 2009-03-12 Irm Llc 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors
CA2720946C (en) * 2008-04-07 2013-05-28 Irm Llc Compounds and compositions as protein kinase inhibitors
AU2009248923B2 (en) * 2008-05-21 2015-01-29 Takeda Pharmaceutical Company Limited Phosphorous derivatives as kinase inhibitors
CA2763717A1 (en) * 2009-06-10 2010-12-16 Cellzome Limited Pyrimidine derivatives as zap-70 inhibitors
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物
RS57771B1 (sr) 2010-12-17 2018-12-31 Novartis Ag Kristalni oblici 5-hloro-n2-(2-izopropoksi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina
CN103384470A (zh) 2010-12-17 2013-11-06 纳幕尔杜邦公司 杀真菌偶氮环酰胺
ME02973B (me) 2010-12-17 2018-07-20 Reata Pharmaceuticals Inc Pirazolil i pirimidinil triciklični enoni kao antioksidantni modulatori inflamacije
CN105294650A (zh) 2014-08-01 2016-02-03 江苏奥赛康药业股份有限公司 一种Ceritinib化合物及其药物组合物
WO2016081538A1 (en) 2014-11-18 2016-05-26 Teva Pharmaceuticals International Gmbh Solid state forms of ceritinib and salts thereof
US9566882B2 (en) 2014-11-21 2017-02-14 Tk Holdings Inc. Airbag module
CN105622577A (zh) 2014-11-29 2016-06-01 江苏先声药业有限公司 一种色瑞替尼的新晶型及其制备方法
MX2017007097A (es) 2014-12-04 2017-09-05 Bristol Myers Squibb Co Combinacion de anticuerpos anti-cs1 y anti-muerte programada 1 (pd1) para tratar cancer (mieloma).
WO2016098070A1 (en) 2014-12-19 2016-06-23 Novartis Ag Crystalline form of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine
EP3328848A1 (en) 2015-07-28 2018-06-06 Zentiva, K.S. Solid forms of ceritinib free base
CN105061397B (zh) 2015-08-07 2018-01-02 武汉英普瑞医药科技有限公司 一种色瑞替尼的c型晶型及其制备方法与应用

Also Published As

Publication number Publication date
KR102325775B1 (ko) 2021-11-12
PH12013501254A1 (en) 2016-07-29
CL2013001723A1 (es) 2013-12-27
AR122395A2 (es) 2022-09-07
RS57771B1 (sr) 2018-12-31
TN2013000216A1 (en) 2014-11-10
DK3121171T3 (en) 2018-12-10
MY164810A (en) 2018-01-30
CN112125884A (zh) 2020-12-25
TWI576344B (zh) 2017-04-01
US9309229B2 (en) 2016-04-12
JP5916752B2 (ja) 2016-05-11
CN106008462A (zh) 2016-10-12
LT3121171T (lt) 2018-11-12
CA2821102A1 (en) 2012-06-21
PT3121171T (pt) 2018-11-27
TW201307299A (zh) 2013-02-16
IL226474A (en) 2016-03-31
RU2016136823A (ru) 2018-12-11
DK2651918T3 (en) 2017-10-23
WO2012082972A1 (en) 2012-06-21
GT201300153A (es) 2014-06-09
MY177742A (en) 2020-09-23
PL2651918T3 (pl) 2017-12-29
HRP20181737T1 (hr) 2018-12-28
JP2013545812A (ja) 2013-12-26
ES2696526T3 (es) 2019-01-16
CN107056751A (zh) 2017-08-18
CY1119474T1 (el) 2018-04-04
EP2651918B1 (en) 2017-07-12
SG10201510082XA (en) 2016-01-28
EP2651918A1 (en) 2013-10-23
CA2821102C (en) 2019-06-11
MA34771B1 (fr) 2013-12-03
CN114989139A (zh) 2022-09-02
MX2013006952A (es) 2013-07-15
ES2643016T3 (es) 2017-11-21
BR112013015000A2 (pt) 2016-08-09
TWI576343B (zh) 2017-04-01
EP3453708B8 (en) 2022-03-16
SG190856A1 (en) 2013-07-31
RU2016136823A3 (OSRAM) 2020-02-06
CY1121017T1 (el) 2019-12-11
RU2746159C2 (ru) 2021-04-08
KR20180032680A (ko) 2018-03-30
PE20140698A1 (es) 2014-06-11
KR20190022903A (ko) 2019-03-06
US20130274279A1 (en) 2013-10-17
ZA201303599B (en) 2014-02-26
EP3453708A1 (en) 2019-03-13
US20160175305A1 (en) 2016-06-23
PL3121171T3 (pl) 2019-01-31
CN106831716A (zh) 2017-06-13
SI3121171T1 (sl) 2018-11-30
IL226474A0 (en) 2013-07-31
CO6801792A2 (es) 2013-11-29
ECSP13012770A (es) 2013-10-31
HUE041845T2 (hu) 2019-05-28
LT2651918T (lt) 2017-10-10
PT2651918T (pt) 2017-10-17
EP3121171A1 (en) 2017-01-25
KR20130130022A (ko) 2013-11-29
KR20200039021A (ko) 2020-04-14
ES2905973T3 (es) 2022-04-12
EP3121171B1 (en) 2018-08-15
SI2651918T1 (sl) 2017-10-30
RU2013132947A (ru) 2015-01-27
EP3453708B1 (en) 2021-10-27
MX338210B (es) 2016-04-07
CN104262324A (zh) 2015-01-07
RU2599785C2 (ru) 2016-10-20
AU2011343775A1 (en) 2013-07-18
RU2599785C3 (ru) 2019-04-24
AR084309A1 (es) 2013-05-08
AU2011343775B2 (en) 2015-12-03
TW201629021A (zh) 2016-08-16
CN103282359A (zh) 2013-09-04
NZ610713A (en) 2014-10-31

Similar Documents

Publication Publication Date Title
HRP20171477T1 (hr) Kristalični oblici od 5-kloro-n2-(2-izopropoksi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina
JP2013545812A5 (OSRAM)
JP2011510632A5 (OSRAM)
HRP20140609T1 (hr) Äśvrsti oblici koji sadrže (+)-2-[1-(3-etoksi-4-metoksifenil)-2-metilsulfoniletil]-4-acetilaminoizoindolin-1,3-dion, njegovi pripravci i njihova upotreba
JP2007509985A5 (OSRAM)
JP2017095457A5 (OSRAM)
HRP20160472T1 (hr) Postupak liječenja proliferativnih bolesti i ostalih patoloških stanja posredovanih djelovanjem kinaze od bcr-abl, c-kit, ddr1, ddr2 ili pdgf-r
ME03744B (me) Spojevi 1-tetrahidropiranilkarbonil-2,3- dihidro-1h-indola, namijenjeni liječenju raka
JP2017511311A5 (OSRAM)
JP2009235086A5 (OSRAM)
Zhu et al. Design, synthesis and 3D-QSAR analysis of novel 2-hydrazinyl-4-morpholinothieno [3, 2-d] pyrimidine derivatives as potential antitumor agents
NZ624315A (en) Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{ 6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl} -1-methyl-urea and salts thereof.
TR201802090T4 (tr) Kanserin tedavisine yönelik monoklonal anti-GT468 antikorlar.
WO2010081443A3 (en) Dosage forms of tyrosine kinase inhibitors
HRP20250236T1 (hr) Kristalni oblici inhibitora atr i njihova uporaba
JP2011511886A5 (OSRAM)
CN103772278A (zh) 一种重要四氢异喹啉衍生物中间体及其合成方法
JP2012509265A5 (OSRAM)
WO2008115150A3 (en) Process for synthesis of clay particles
CN105646353B (zh) 塞来昔布厄贝沙坦共无定形物
Shang et al. Novel pharmaceutical salt and solvates of rebamipide: Preparations, structural analysis and properties
AR111906A1 (es) Formas cristalinas de 5-bromo-2,6-di(1h-pirazol-1-il)pirimidin-4-amina y sales
RU2016132469A (ru) S-кристаллическая форма хлористоводородного ивабрадина, способ ее получения и фармацевтическая композиция на основе этой формы
CN104230781A (zh) 一种合成卤代3-甲基吲哚化合物的方法
JP2010513552A5 (OSRAM)